share_log

UBS Maintains Buy on AtriCure, Raises Price Target to $40

UBS Maintains Buy on AtriCure, Raises Price Target to $40

瑞银UBS维持对atricure的买入评级,将目标股价上调至40美元
Benzinga ·  10/30 21:34  · 评级/大行评级

UBS analyst Danielle Antalffy maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $35 to $40.

瑞银分析师丹妮尔·安塔尔菲维持AtriCure(纳斯达克股票代码:ATRC)的买入并将目标股价从35美元上调至40美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发